Clinical Trial

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-08; most recent amendment 2025-05-16.
Status change: Recruiting → Active, Not Recruiting 2025-05-16
Status change: Not Yet Recruiting → Recruiting 2024-01-03
Trial Details
NCT Number NCT06082635
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: Sun Yat-Sen University Cancer Center
Conditions Non Small Cell Lung Cancer
Enrollment 321 participants
Start Date 2023-12-14
Primary Completion 2026-04-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-18